Get the Stockscreener App
9.14
0.77%
0.07
Kyntra Bio Inc stock is traded at $9.14, with a volume of 10,628.
It is up +0.77% in the last 24 hours and up +0.00% over the past month.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
See More
Previous Close:
$9.07
Open:
$9.1
24h Volume:
10,628
Relative Volume:
8.34
Market Cap:
$36.98M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.02
$9.3843
1-Week Range:
$9.02
$9.58
52-Week Range:
$9.02
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Name
Kyntra Bio Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO
Compare KYNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
9.14 | 36.69M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
View All
Kyntra Bio Inc Stock (KYNB) Latest News
FibroGen rebrands as Kyntra Bio, refocuses on oncology - TipRanks
FibroGen announces rebrand as Kyntra Bio - TipRanks
FibroGen stock rises after announcing rebrand to Kyntra Bio - Investing.com
FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB - Investing.com
FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewswire
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
FibroGen Sells China Unit To AstraZeneca And Refocuses - Finimize
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million - GlobeNewswire
Major Regulatory Win: FibroGen's $815M China Business Sale to AstraZeneca Gets Green Light from Regulators - Stock Titan
FGENFibrogen Inc Latest Stock News & Market Updates - Stock Titan
FibroGen Announces 1-for-25 Reverse Stock Split - marketscreener.com
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - marketscreener.com
FibroGen: Q1 Earnings Snapshot - marketscreener.com
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - marketscreener.com
FibroGen: Q4 Earnings Snapshot - marketscreener.com
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - marketscreener.com
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million - marketscreener.com
FibroGen : Appoints David DeLucia as Chief Financial Officer Form 8 K - marketscreener.com
FibroGen: Q3 Earnings Snapshot - marketscreener.com
FibroGen to Report Third Quarter 2024 Financial Results - marketscreener.com
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference - marketscreener.com
FibroGen: Q2 Earnings Snapshot - marketscreener.com
FibroGen to Report Second Quarter 2024 Financial Results - marketscreener.com
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference - marketscreener.com
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference - marketscreener.com
FibroGen regains rights to anemia drug from AstraZeneca - marketscreener.com
Fibrogen, Inc. Announces Chief Executive Officer Changes - marketscreener.com
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? - The Motley Fool
Meet Ananth Narayanan, Ex-Myntra CEO, Mensa Brands founder: Know about his journey, education & family - The Financial Express
Goldman Sachs Adjusts Price Target on FibroGen to $9 From $8, Maintains Sell Rating - marketscreener.com
FibroGen, Inc. Appoints John Hunter as Chief Scientific Officer - marketscreener.com
FibroGen to Present at Upcoming Investor Conferences - GlobeNewswire
Cue Biopharma (CUE) Stock Price, Quote, News & History - Benzinga
FibroGen, Inc. Appoints Thane Wettig as Chief Commercial Officer - marketscreener.com
FibroGen, Inc. Announces Resignation of James Schoeneck as Interim President - marketscreener.com
FIBROGEN INC : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Trio Wins Nobel for Oxygen Studies That Led to Anemia Drugs - Bloomberg
FibroGen, Inc. Announces Executive Changes - marketscreener.com
FibroGen, Inc. Appoints Maykin Ho as an Independent Director to Board of Directors - marketscreener.com
Kyntra Bio Inc Stock (KYNB) Financials Data
There is no financial data for Kyntra Bio Inc (KYNB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Kyntra Bio Inc Stock (KYNB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
| Schoeneck James A | Director |
Jun 30 '25 |
Buy |
5.07 |
23,567 |
119,485 |
39,666 |
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):